Literature DB >> 1851971

Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography.

F T Vertosick1, R G Selker, V C Arena.   

Abstract

We report 25 verified cases of well-differentiated cerebral astrocytomas in adults treated between 1978 and 1988. All patients were diagnosed by computed tomographic (CT) scans, with 5 undergoing a craniotomy for debulking and 20 undergoing a biopsy alone. The median survival for the entire group was 8.2 years, the longest survival yet reported for a series of patients with these tumors. A review of the literature suggests that the longer survival observed in more recent series is the result of the earlier diagnosis of tumors afforded by modern brain imaging. Twenty of our patients presented with seizures in the absence of any other focal findings and would probably not have had a biopsy in the era before CT scans until their tumors had progressed. Only 8% of our patients had papilledema at the time of presentation, in contrast to almost half of the patients with low-grade astrocytomas reported before 1975, supporting the hypothesis that patients in the CT era are diagnosed earlier. None of our patients died from progressive low-grade disease. One patient died from a squamous cell cancer, and 7 died as a consequence of their tumors dedifferentiating into a more malignant astrocytoma or glioblastoma multiforme, with a median time of approximately 5 years after the diagnosis. Our findings, together with the available data in the literature, suggest that death from a focal low-grade astrocytoma, in the absence of malignant degeneration, may be a rare event. Consequently, future therapeutic efforts should be targeted at preventing dedifferentiation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1851971     DOI: 10.1097/00006123-199104000-00002

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  46 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 3.  Malignant transformation in pediatric spinal intramedullary tumors: case-based update.

Authors:  E Winograd; N Pencovich; M Yalon; D Soffer; L Beni-Adani; S Constantini
Journal:  Childs Nerv Syst       Date:  2012-07-10       Impact factor: 1.475

Review 4.  Designing clinical trials for brain tumors: the next generation.

Authors:  Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

5.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma.

Authors:  K Lote; T Egeland; B Hager; K Skullerud; H Hirschberg
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

6.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery.

Authors:  M L van Veelen; C J Avezaat; J M Kros; W van Putten; C Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

7.  Proliferative activity and prognosis of low-grade astrocytomas.

Authors:  D Schiffer; P Cavalla; A Chiò; P Richiardi; M T Giordana
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 8.  Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome.

Authors:  M S Berger; R C Rostomily
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 9.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro.

Authors:  J J Bernstein; W J Goldberg; E R Laws
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.